Catalent signs partnership deal with Toyobo Biologics

To co-promote GPex technology in the Japanese market

Catalent Pharma Solutions, a US provider of drug and biologic development services, delivery technologies and supply solutions, and Toyobo Biologics, are to co-promote Catalent’s proprietary GPEx technology in the Japanese market. TBI is a biologics supplier and contract provider of large-scale clinical and commercial bioreactors in Japan.

GPEx technology is used for mammalian cell line development. Catalent says it creates stable, high expression cell lines that speed up biologics drug development to the clinic taking a third of the time of traditional approaches.

TBI operates a GMP manufacturing plant with bioreactors ranging from 100L up to 4,000L in Shiga, Japan.

‘We are confident TBI’s strong position in the Japanese market, combined with access to Catalent’s proprietary GPEx technology, will create new opportunities to enhance our ability to serve our customers in the region,’ said Yukihiro Sogabe, president of TBI. ‘We look forward to capitalising on these opportunities and leveraging future successes together.’